Informations générales (source: ClinicalTrials.gov)

NCT03622983 En recrutement IDF
Cohort of Patients With Pelvic Gynecological Cancer: Constitution of a Collection of Biological Samples With Radioclinical Characterization (PELVIMASS2)
Observational
  • Endométriose
  • Tumeurs du bassin
Centre Hospitalier Intercommunal Creteil (Voir sur ClinicalTrials)
mai 2017
août 2037
29 juin 2024
The management of pelvic gynecological cancers (PGC) is based on the determination of extension to guide treatments. The biology of the CGP is constantly evolving and personalized medicine adapted to this biology is currently in full development. For example, sequencing ovarian tumors can select patients who can benefit from anti-PARP therapy. There is therefore a need for patients to have biological samples of their tumor. Various studies on ovarian, endometrial and cervical cancer have sought to identify the factors predictive of recurrence of these cancers. The results obtained are very promising. This study will permit to collect biological samples and detailed clinical data that would allow to test hypotheses and develop a personalized medicine based on clinical and biological characteristics of patients.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CHI DE CRETEIL Cyril TOUBOUL En recrutement IDF 29/03/2024 01:27:03  Contacter
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
AP-HP - Hôpital Tenon Cyril Touboul En recrutement IDF Contact (sur clinicalTrials)

Critères

Femme
Inclusion Criteria:

- Diagnosis of pelvic gynecological cancer posed on initial histological analysis or
during recurrence;

- Or diagnosis of endometriosis on histology or imaging

- Age ≥ 18 years;

- Affiliation to the general social security scheme;

- Consent signed.


- Refusal of the patient;

- Non-affiliation to the general social security scheme.